Candel Therapeutics, Inc. (CADL)
| Market Cap | 778.96M +156.1% |
| Revenue (ttm) | n/a |
| Net Income | -88.53M |
| EPS | -1.44 |
| Shares Out | 76.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 878,803 |
| Open | 10.29 |
| Previous Close | 10.16 |
| Day's Range | 10.03 - 10.37 |
| 52-Week Range | 4.35 - 14.00 |
| Beta | -0.31 |
| Analysts | Strong Buy |
| Price Target | 21.75 (+113.65%) |
| Est. Earnings | Nov 12, 2026 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price target is $21.75, which is an increase of 113.65% from the latest price.
News
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel announces final phase 2a trial of aglatimagene, valacyclovir
Candel Therapeutics (CADL) announced the publication of final phase 2a clinical trial results of aglatimagene besadenovec plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequate...
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics announces data from phase 2 PrTK05 trial
Candel Therapeutics (CADL) announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial in patients with intermediate-risk localized prostate cancer. These data, together with hi...
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics announces new data on aglatimagene besadenovec
Candel Therapeutics (CADL) announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk ...
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics upgraded to Buy from Neutral at BofA
BofA upgraded Candel Therapeutics (CADL) to Buy from Neutral with a price target of $18, up from $12. A mature prostate cancer package, on track for a BLA in Q4,…
Candel Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two viral immunotherapies are advancing, with aglatimagene showing strong phase III results in prostate cancer and a BLA submission planned by year-end. Commercial launch will target top accounts, with positive payer feedback and a focus on integrating into radiation workflows. Key upcoming milestones include biomarker data and regulatory filings.
Candel Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Viral immunotherapy programs are advancing, with aglatimagen showing significant efficacy in prostate cancer and moving toward BLA submission. Manufacturing and regulatory milestones are on track, with new biomarker and long-term survivor data expected by year-end.
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics to Present at September Investor Conferences
NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics price target raised to $12 from $9 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Candel Therapeutics (CADL) to $12 from $9 and keeps a Neutral rating on the shares. The firm adjusted targets for…
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Earnings release: Q2 2026
Candel Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Candel Therapeutics Quarterly report: Q2 2026
Candel Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Candel Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
The conference highlighted positive phase III results for aglatimagene in prostate cancer, strong physician enthusiasm, and a significant commercial opportunity. Upcoming data will further detail immune engagement, while new trials in lung cancer and glioblastoma advance.
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston
NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics initiated with a Buy at Stifel
Stifel analyst Stephen Willey initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $22 price target The firm views the company’s aglatimagene as a “differentiated” and “versatile” lo...
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Slides: Corporate presentation
Candel Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...